服務(wù)承諾:
工作時(shí)間內(nèi)提供免費(fèi)的技術(shù)咨詢(xún)和指導(dǎo) 。我公司的銷(xiāo)售工程師經(jīng)過(guò)專(zhuān)業(yè)培訓(xùn)的,將為您提供滿(mǎn)意的產(chǎn)品和真誠(chéng)的服務(wù)。
普魯蘭糖號(hào):9057-02-7
英文名稱(chēng):Pululan
其他名稱(chēng):茁霉多糖;短梗霉多糖;出芽短梗酶多糖;出芽短梗孢糖;普魯蘭多糖
號(hào):9057-02-7
(C37H62O30)n
級(jí)別:BR
含量:≥98%
重金屬:≤10ppm
干燥失重:≤8.0%
性狀(以下信息僅供參考):白色粉末。普魯蘭糖是麥芽三糖用α-1.6鍵連結(jié)起來(lái)的多糖。無(wú)味無(wú)臭。易溶于水、二甲基甲酰胺,不產(chǎn)生膠凝作用,溶液粘稠穩(wěn)定,呈中性。不溶于醇、醚、油類(lèi)。溶液的粘稠性與阿拉伯膠相同,具有非常優(yōu)良的耐鹽、耐酶、耐熱、耐PH值變化的增稠作用。造膜性強(qiáng),其水溶液在金屬板上干燥后形成的薄膜,對(duì)氧、氮的阻氣性強(qiáng)。易形成水溶性的可食薄膜。與其他水溶性高分子物質(zhì)的相容性良好
用途:本品僅供科研,不得用于其它用途。
保存:RT 普魯蘭糖號(hào):9057-02-7儲(chǔ)存條件:
避光、干燥陰涼處封閉貯存,嚴(yán)禁與有毒、有害物品混放、混運(yùn)。本品為非危險(xiǎn) 產(chǎn)品可按一般化學(xué)品運(yùn)輸,輕搬動(dòng)輕放,防止日曬、雨淋!受熱、受潮、受光后易喪失活力,保存期短,因此貯存和運(yùn)輸條件比較苛刻。
運(yùn)輸:汽車(chē)運(yùn)輸、EMS郵政快遞,申通快遞等, 款到上海3天內(nèi)發(fā)貨;
售后:如您對(duì)我們的產(chǎn)品服務(wù)及技術(shù)指標(biāo)有特殊要求,請(qǐng)及時(shí)通知我方。
存儲(chǔ):應(yīng)貯存在干燥清潔避光的環(huán)境中,嚴(yán)禁與有毒物質(zhì)混放,以免污染(保質(zhì)期為兩年)。
普魯蘭糖號(hào):9057-02-7主要優(yōu)級(jí)純、分級(jí)純和化學(xué)純3種:
(1)優(yōu)級(jí)純(GR:Guaranteed reagent),又稱(chēng)一級(jí)品或保證試劑,99.8%,這種試劑純度Z高,雜質(zhì)含量Z低,適合于重要精密的分析工作和科學(xué)研究工作,使用綠色瓶簽。
(2)分析純(AR),又稱(chēng)二級(jí)試劑,純度很高,99.7%,略次于優(yōu)級(jí)純,適合于重要分析及一般研究工作,使用紅色瓶簽。
(3)化學(xué)純(CP),又稱(chēng)三級(jí)試劑,≥ 99.5%,純度與分析純相差較大,適用于工礦、學(xué)校一般分析工作。使用藍(lán)色(深藍(lán)色)標(biāo)簽。
(4)實(shí)驗(yàn)試劑(LR:Laboratory reagent),又稱(chēng)四級(jí)試劑。
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Synucleins are small soluble proteins expressed primarily in neural tissues and in certain tumors. The family includes 3 known proteins, alpha synuclein, beta synuclein and gamma synuclein. All synucleins have in common a highly conserved alpha helical lipid binding motif with similarity to the class A2 lipid binding domains of the exchangeable apolipoproteins. The alpha and beta synuclein proteins are found primarily in brain tissue, where they are seen mainly in pre synaptic terminals. Alpha synuclein is believed to be a major component of Lewy bodies in Parkinson’s disease. Mutations in alpha synuclein are associated with rare familial cases of early onset Parkinson’s disease, Alzheimer’s disease and several other neurodegenerative illnesses.
Function : May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
Subunit : Soluble monomer which can form filamentous aggregates. Interacts with UCHL1 (By similarity). Interacts with phospholipase D and histones.
Subcellular Location : Cytoplasmic. Membrane bound in dopaminergic neurons. Also found in the nucleus.
Tissue Specificity : Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.
Post-translational modifications : Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
Ubiquitinated. The predominant conjugate is the diubiquitinated form (By similarity).
DISEASE : Note=Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.
Defects in SNCA are the cause of Parkinson disease type 1 (PARK1) [MIM:168601]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.
Defects in SNCA are the cause of Parkinson disease type 4 (PARK4) [MIM:605543]. A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia.
Defects in SNCA are the cause of dementia Lewy body (DLB) [MIM:127750]. A neurodegenerative disorder clinically characterized by mental impairment leading to dementia, parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.
Similarity : Belongs to the synuclein family.
Database links : UniProtKB/Swiss-Prot: P37840.1 UniProtKB/Swiss-Prot: Q16143.1
英文名稱(chēng) Anti-STOML3
中文名稱(chēng) 嗅覺(jué)神經(jīng)相關(guān)蛋白STOML3抗體
別 名 erythrocyte band 7 integral membrane protein; SLP-3; stomatin (EPB72) like 3; stomatin (EPB72)-like 3; stomatin like 3; stomatin like protein 3; stomatin-like 3; STOML3; STOM_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來(lái)源 Rabbit
克隆類(lèi)型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep
產(chǎn)品類(lèi)型 一抗
研究領(lǐng)域 細(xì)胞生物 神經(jīng)生物學(xué)
蛋白分子量 predicted molecular weight: 32, 64kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human STOML3 (170-218aa)
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
(石蠟切片需做抗原修復(fù))
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 This gene encodes a member of a highly conserved family of integral membrane proteins. The encoded protein localizes to the cell membrane of red blood cells and other cell types, where it may regulate ion channels and transporters. Loss of localization of the encoded protein is associated with hereditary stomatocytosis, a form of hemolytic anemia. There is a pseudogene for this gene on chromosome 6. Alternative splicing results in multiple transcript variants.
Function : Specific function of STOML3 remains unknown.
Subunit : Homooligomer containing between 9 and 12 monomers. Interacts with ASIC1, ASIC2 and ASIC3. Interacts with LANCL1.
Subcellular Location : Single pass type III membrane protein
Tissue Specificity : Widely expressed.
Similarity : Belongs to the band 7/mec-2 family.
Database links : UniProtKB/Swiss-Prot: P27105.3
英文名稱(chēng) Anti-SLC14A2/UT-A
中文名稱(chēng) 尿素轉(zhuǎn)運(yùn)型糖蛋白A2抗體
別 名 HUT2; kidney; MGC119566; MGC119567; Slc14a2; Solute carrier family 14 (urea transporter), member 2; Solute carrier family 14 member 2; Urea transporter 2; Urea transporter; Urea transporter, kidney; UT-A2; UT2; UT2_HUMAN; UTA; UTR; FLJ16167; hUT-A6.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來(lái)源 Rabbit
克隆類(lèi)型 polyclonal
交叉反應(yīng) Human, Mouse, Rat
產(chǎn)品類(lèi)型 一抗